APO Research
Talk to an analyst

APO RESEARCH · REPORT

CAR-T Cellular Immunotherapy

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global CAR-T Cellular Immunotherapy Market Analysis and Forecast 2026-2032

2 January 2026194 pages

Choose your research edition.

Industry ResearchCAR-T Cellular Immunotherapy Industry Research Report 2026109 pages · $2,950 USDIndustry Growth & TrendsGlobal CAR-T Cellular Immunotherapy Industry Growth and Trends Forecast to 203264 pages · $3,450 USDMarket StructureGlobal CAR-T Cellular Immunotherapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032177 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal CAR-T Cellular Immunotherapy Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal CAR-T Cellular Immunotherapy Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global CAR-T Cellular Immunotherapy market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for CAR-T Cellular Immunotherapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for CAR-T Cellular Immunotherapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for CAR-T Cellular Immunotherapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for CAR-T Cellular Immunotherapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of CAR-T Cellular Immunotherapy include Novartis, Gilead Sciences, Fosun Kite Biotechnology and Bristol-Myers Squibb, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for CAR-T Cellular Immunotherapy, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of CAR-T Cellular Immunotherapy, also provides the revenue of main regions and countries. Of the upcoming market potential for CAR-T Cellular Immunotherapy, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the CAR-T Cellular Immunotherapy revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global CAR-T Cellular Immunotherapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for CAR-T Cellular Immunotherapy revenue, projected growth trends, production technology, application and end-user industry.

CAR-T Cellular Immunotherapy Segment by Company

Novartis

Gilead Sciences

Fosun Kite Biotechnology

Bristol-Myers Squibb

CAR-T Cellular Immunotherapy Segment by Type

Allogeneic

Autologous

CAR-T Cellular Immunotherapy Segment by Application

Hospital

Pharmacy

Other

CAR-T Cellular Immunotherapy Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CAR-T Cellular Immunotherapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of CAR-T Cellular Immunotherapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CAR-T Cellular Immunotherapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of CAR-T Cellular Immunotherapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of CAR-T Cellular Immunotherapy company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, CAR-T Cellular Immunotherapy revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global CAR-T Cellular Immunotherapy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Allogeneic Major Player Table 3. Autologous Major Player Table 4. Global CAR-T Cellular Immunotherapy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Major Player Table 6. Pharmacy Major Player Table 7. Other Major Player Table 8. CAR-T Cellular Immunotherapy Industry Trends Table 9. CAR-T Cellular Immunotherapy Industry Drivers Table 10. CAR-T Cellular Immunotherapy Industry Opportunities and Challenges Table 11. CAR-T Cellular Immunotherapy Industry Restraints Table 12. Global CAR-T Cellular Immunotherapy Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global CAR-T Cellular Immunotherapy Market Size by Region (2021-2026) & (US$ Million) Table 14. Global CAR-T Cellular Immunotherapy Market Share by Region (2021-2026) Table 15. Global CAR-T Cellular Immunotherapy Market Size by Region (2027-2032) & (US$ Million) Table 16. Global CAR-T Cellular Immunotherapy Market Share by Region (2027-2032) Table 17. Global CAR-T Cellular Immunotherapy Revenue by Players (US$ Million) & (2021-2026) Table 18. Global CAR-T Cellular Immunotherapy Revenue Market Share by Players (2021-2026) Table 19. Global CAR-T Cellular Immunotherapy Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global CAR-T Cellular Immunotherapy Key Players Headquarters & Area Served Table 21. Global CAR-T Cellular Immunotherapy Players, Product Type & Application Table 22. Global CAR-T Cellular Immunotherapy Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global CAR-T Cellular Immunotherapy by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global CAR-T Cellular Immunotherapy Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global CAR-T Cellular Immunotherapy Revenue by Type (2021-2026) & (US$ Million) Table 27. Global CAR-T Cellular Immunotherapy Revenue by Type (2027-2032) & (US$ Million) Table 28. Global CAR-T Cellular Immunotherapy Revenue Market Share by Type (2021-2026) Table 29. Global CAR-T Cellular Immunotherapy Revenue Market Share by Type (2027-2032) Table 30. Global CAR-T Cellular Immunotherapy Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global CAR-T Cellular Immunotherapy Revenue by Application (2021-2026) & (US$ Million) Table 32. Global CAR-T Cellular Immunotherapy Revenue by Application (2027-2032) & (US$ Million) Table 33. Global CAR-T Cellular Immunotherapy Revenue Market Share by Application (2021-2026) Table 34. Global CAR-T Cellular Immunotherapy Revenue Market Share by Application (2027-2032) Table 35. Novartis Company Information Table 36. Novartis Business Overview Table 37. Novartis CAR-T Cellular Immunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Novartis CAR-T Cellular Immunotherapy Product Portfolio Table 39. Novartis Recent Development Table 40. Gilead Sciences Company Information Table 41. Gilead Sciences Business Overview Table 42. Gilead Sciences CAR-T Cellular Immunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Gilead Sciences CAR-T Cellular Immunotherapy Product Portfolio Table 44. Gilead Sciences Recent Development Table 45. Fosun Kite Biotechnology Company Information Table 46. Fosun Kite Biotechnology Business Overview Table 47. Fosun Kite Biotechnology CAR-T Cellular Immunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Fosun Kite Biotechnology CAR-T Cellular Immunotherapy Product Portfolio Table 49. Fosun Kite Biotechnology Recent Development Table 50. Bristol-Myers Squibb Company Information Table 51. Bristol-Myers Squibb Business Overview Table 52. Bristol-Myers Squibb CAR-T Cellular Immunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Bristol-Myers Squibb CAR-T Cellular Immunotherapy Product Portfolio Table 54. Bristol-Myers Squibb Recent Development Table 55. North America CAR-T Cellular Immunotherapy Revenue by Type (2021-2026) & (US$ Million) Table 56. North America CAR-T Cellular Immunotherapy Revenue by Type (2027-2032) & (US$ Million) Table 57. North America CAR-T Cellular Immunotherapy Revenue by Application (2021-2026) & (US$ Million) Table 58. North America CAR-T Cellular Immunotherapy Revenue by Application (2027-2032) & (US$ Million) Table 59. North America CAR-T Cellular Immunotherapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 60. North America CAR-T Cellular Immunotherapy Revenue by Country (2021-2026) & (US$ Million) Table 61. North America CAR-T Cellular Immunotherapy Revenue by Country (US$ Million) & (2027-2032) Table 62. Europe CAR-T Cellular Immunotherapy Revenue by Type (2021-2026) & (US$ Million) Table 63. Europe CAR-T Cellular Immunotherapy Revenue by Type (2027-2032) & (US$ Million) Table 64. Europe CAR-T Cellular Immunotherapy Revenue by Application (2021-2026) & (US$ Million) Table 65. Europe CAR-T Cellular Immunotherapy Revenue by Application (2027-2032) & (US$ Million) Table 66. Europe CAR-T Cellular Immunotherapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 67. Europe CAR-T Cellular Immunotherapy Revenue by Country (2021-2026) & (US$ Million) Table 68. Europe CAR-T Cellular Immunotherapy Revenue by Country (US$ Million) & (2027-2032) Table 69. China CAR-T Cellular Immunotherapy Revenue by Type (2021-2026) & (US$ Million) Table 70. China CAR-T Cellular Immunotherapy Revenue by Type (2027-2032) & (US$ Million) Table 71. China CAR-T Cellular Immunotherapy Revenue by Application (2021-2026) & (US$ Million) Table 72. China CAR-T Cellular Immunotherapy Revenue by Application (2027-2032) & (US$ Million) Table 73. Asia CAR-T Cellular Immunotherapy Revenue by Type (2021-2026) & (US$ Million) Table 74. Asia CAR-T Cellular Immunotherapy Revenue by Type (2027-2032) & (US$ Million) Table 75. Asia CAR-T Cellular Immunotherapy Revenue by Application (2021-2026) & (US$ Million) Table 76. Asia CAR-T Cellular Immunotherapy Revenue by Application (2027-2032) & (US$ Million) Table 77. Asia CAR-T Cellular Immunotherapy Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 78. Asia CAR-T Cellular Immunotherapy Revenue by Region (US$ Million) & (2021-2026) Table 79. Asia CAR-T Cellular Immunotherapy Revenue by Region (US$ Million) & (2027-2032) Table 80. SAMEA CAR-T Cellular Immunotherapy Revenue by Type (2021-2026) & (US$ Million) Table 81. SAMEA CAR-T Cellular Immunotherapy Revenue by Type (2027-2032) & (US$ Million) Table 82. SAMEA CAR-T Cellular Immunotherapy Revenue by Application (2021-2026) & (US$ Million) Table 83. SAMEA CAR-T Cellular Immunotherapy Revenue by Application (2027-2032) & (US$ Million) Table 84. SAMEA CAR-T Cellular Immunotherapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 85. SAMEA CAR-T Cellular Immunotherapy Revenue by Country (2021-2026) & (US$ Million) Table 86. SAMEA CAR-T Cellular Immunotherapy Revenue by Country (US$ Million) & (2027-2032) Table 87. Research Programs/Design for This Report Table 88. Authors List of This Report Table 89. Secondary Sources Table 90. Primary Sources List of Figures Figure 1. CAR-T Cellular Immunotherapy Image Figure 2. Global CAR-T Cellular Immunotherapy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global CAR-T Cellular Immunotherapy Market Size Share 2021 VS 2025 VS 2032 Figure 4. Allogeneic Image Figure 5. Autologous Image Figure 6. Global CAR-T Cellular Immunotherapy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global CAR-T Cellular Immunotherapy Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Image Figure 9. Pharmacy Image Figure 10. Other Image Figure 11. Global CAR-T Cellular Immunotherapy Market Size (US$ Million) & (2021-2032) Figure 12. Global CAR-T Cellular Immunotherapy Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global CAR-T Cellular Immunotherapy Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global CAR-T Cellular Immunotherapy Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global CAR-T Cellular Immunotherapy Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global CAR-T Cellular Immunotherapy Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global CAR-T Cellular Immunotherapy Revenue Market Share by Type (2021-2032) Figure 19. Global CAR-T Cellular Immunotherapy Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global CAR-T Cellular Immunotherapy Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global CAR-T Cellular Immunotherapy Revenue Market Share by Application (2021-2032) Figure 22. North America CAR-T Cellular Immunotherapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America CAR-T Cellular Immunotherapy Revenue Share by Type (2021-2032) Figure 24. North America CAR-T Cellular Immunotherapy Revenue Share by Application (2021-2032) Figure 25. North America CAR-T Cellular Immunotherapy Revenue Share by Country (2021-2032) Figure 26. United States CAR-T Cellular Immunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada CAR-T Cellular Immunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico CAR-T Cellular Immunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe CAR-T Cellular Immunotherapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe CAR-T Cellular Immunotherapy Revenue Share by Type (2021-2032) Figure 31. Europe CAR-T Cellular Immunotherapy Revenue Share by Application (2021-2032) Figure 32. Europe CAR-T Cellular Immunotherapy Revenue Share by Country (2021-2032) Figure 33. Germany CAR-T Cellular Immunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France CAR-T Cellular Immunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. CAR-T Cellular Immunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy CAR-T Cellular Immunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain CAR-T Cellular Immunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia CAR-T Cellular Immunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands CAR-T Cellular Immunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries CAR-T Cellular Immunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China CAR-T Cellular Immunotherapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China CAR-T Cellular Immunotherapy Revenue Share by Type (2021-2032) Figure 43. China CAR-T Cellular Immunotherapy Revenue Share by Application (2021-2032) Figure 44. Asia CAR-T Cellular Immunotherapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia CAR-T Cellular Immunotherapy Revenue Share by Type (2021-2032) Figure 46. Asia CAR-T Cellular Immunotherapy Revenue Share by Application (2021-2032) Figure 47. Asia CAR-T Cellular Immunotherapy Revenue Share by Region (2021-2032) Figure 48. Japan CAR-T Cellular Immunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea CAR-T Cellular Immunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India CAR-T Cellular Immunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia CAR-T Cellular Immunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan CAR-T Cellular Immunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia CAR-T Cellular Immunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA CAR-T Cellular Immunotherapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA CAR-T Cellular Immunotherapy Revenue Share by Type (2021-2032) Figure 56. SAMEA CAR-T Cellular Immunotherapy Revenue Share by Application (2021-2032) Figure 57. SAMEA CAR-T Cellular Immunotherapy Revenue Share by Country (2021-2032) Figure 58. Brazil CAR-T Cellular Immunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina CAR-T Cellular Immunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile CAR-T Cellular Immunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia CAR-T Cellular Immunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru CAR-T Cellular Immunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia CAR-T Cellular Immunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel CAR-T Cellular Immunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE CAR-T Cellular Immunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey CAR-T Cellular Immunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran CAR-T Cellular Immunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt CAR-T Cellular Immunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Allogeneic
  • Autologous
Applications
  • Hospital
  • Pharmacy
  • Other
Companies covered
  • Novartis
  • Gilead Sciences
  • Fosun Kite Biotechnology
  • Bristol-Myers Squibb

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 CAR-T Cellular Immunotherapy Market by Type
  3. 1.2.1 Global CAR-T Cellular Immunotherapy Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Allogeneic
  5. 1.2.3 Autologous
  6. 1.3 CAR-T Cellular Immunotherapy Market by Application
  7. 1.3.1 Global CAR-T Cellular Immunotherapy Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital
  9. 1.3.3 Pharmacy
  10. 1.3.4 Other
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 CAR-T Cellular Immunotherapy Market Dynamics
  1. 2.1 CAR-T Cellular Immunotherapy Industry Trends
  2. 2.2 CAR-T Cellular Immunotherapy Industry Drivers
  3. 2.3 CAR-T Cellular Immunotherapy Industry Opportunities and Challenges
  4. 2.4 CAR-T Cellular Immunotherapy Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global CAR-T Cellular Immunotherapy Market Perspective (2021-2032)
  2. 3.2 Global CAR-T Cellular Immunotherapy Growth Trends by Region
  3. 3.2.1 Global CAR-T Cellular Immunotherapy Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global CAR-T Cellular Immunotherapy Market Size by Region (2021-2026)
  5. 3.2.3 Global CAR-T Cellular Immunotherapy Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global CAR-T Cellular Immunotherapy Revenue by Players
  2. 4.1.1 Global CAR-T Cellular Immunotherapy Revenue by Players (2021-2026)
  3. 4.1.2 Global CAR-T Cellular Immunotherapy Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global CAR-T Cellular Immunotherapy Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global CAR-T Cellular Immunotherapy Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global CAR-T Cellular Immunotherapy Key Players Headquarters & Area Served
  7. 4.4 Global CAR-T Cellular Immunotherapy Players, Product Type & Application
  8. 4.5 Global CAR-T Cellular Immunotherapy Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global CAR-T Cellular Immunotherapy Market CR5 and HHI
  11. 4.6.3 2025 CAR-T Cellular Immunotherapy Tier 1, Tier 2, and Tier 3
5 CAR-T Cellular Immunotherapy Market Size by Type
  1. 5.1 Global CAR-T Cellular Immunotherapy Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global CAR-T Cellular Immunotherapy Revenue by Type (2021-2032)
  3. 5.3 Global CAR-T Cellular Immunotherapy Revenue Market Share by Type (2021-2032)
6 CAR-T Cellular Immunotherapy Market Size by Application
  1. 6.1 Global CAR-T Cellular Immunotherapy Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global CAR-T Cellular Immunotherapy Revenue by Application (2021-2032)
  3. 6.3 Global CAR-T Cellular Immunotherapy Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Novartis
  2. 7.1.1 Novartis Company Information
  3. 7.1.2 Novartis Business Overview
  4. 7.1.3 Novartis CAR-T Cellular Immunotherapy Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Novartis CAR-T Cellular Immunotherapy Product Portfolio
  6. 7.1.5 Novartis Recent Developments
  7. 7.2 Gilead Sciences
  8. 7.2.1 Gilead Sciences Company Information
  9. 7.2.2 Gilead Sciences Business Overview
  10. 7.2.3 Gilead Sciences CAR-T Cellular Immunotherapy Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Gilead Sciences CAR-T Cellular Immunotherapy Product Portfolio
  12. 7.2.5 Gilead Sciences Recent Developments
  13. 7.3 Fosun Kite Biotechnology
  14. 7.3.1 Fosun Kite Biotechnology Company Information
  15. 7.3.2 Fosun Kite Biotechnology Business Overview
  16. 7.3.3 Fosun Kite Biotechnology CAR-T Cellular Immunotherapy Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Fosun Kite Biotechnology CAR-T Cellular Immunotherapy Product Portfolio
  18. 7.3.5 Fosun Kite Biotechnology Recent Developments
  19. 7.4 Bristol-Myers Squibb
  20. 7.4.1 Bristol-Myers Squibb Company Information
  21. 7.4.2 Bristol-Myers Squibb Business Overview
  22. 7.4.3 Bristol-Myers Squibb CAR-T Cellular Immunotherapy Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Bristol-Myers Squibb CAR-T Cellular Immunotherapy Product Portfolio
  24. 7.4.5 Bristol-Myers Squibb Recent Developments
8 North America
  1. 8.1 North America CAR-T Cellular Immunotherapy Revenue (2021-2032)
  2. 8.2 North America CAR-T Cellular Immunotherapy Revenue by Type (2021-2032)
  3. 8.2.1 North America CAR-T Cellular Immunotherapy Revenue by Type (2021-2026)
  4. 8.2.2 North America CAR-T Cellular Immunotherapy Revenue by Type (2027-2032)
  5. 8.3 North America CAR-T Cellular Immunotherapy Revenue Share by Type (2021-2032)
  6. 8.4 North America CAR-T Cellular Immunotherapy Revenue by Application (2021-2032)
  7. 8.4.1 North America CAR-T Cellular Immunotherapy Revenue by Application (2021-2026)
  8. 8.4.2 North America CAR-T Cellular Immunotherapy Revenue by Application (2027-2032)
  9. 8.5 North America CAR-T Cellular Immunotherapy Revenue Share by Application (2021-2032)
  10. 8.6 North America CAR-T Cellular Immunotherapy Revenue by Country
  11. 8.6.1 North America CAR-T Cellular Immunotherapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America CAR-T Cellular Immunotherapy Revenue by Country (2021-2026)
  13. 8.6.3 North America CAR-T Cellular Immunotherapy Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe CAR-T Cellular Immunotherapy Revenue (2021-2032)
  2. 9.2 Europe CAR-T Cellular Immunotherapy Revenue by Type (2021-2032)
  3. 9.2.1 Europe CAR-T Cellular Immunotherapy Revenue by Type (2021-2026)
  4. 9.2.2 Europe CAR-T Cellular Immunotherapy Revenue by Type (2027-2032)
  5. 9.3 Europe CAR-T Cellular Immunotherapy Revenue Share by Type (2021-2032)
  6. 9.4 Europe CAR-T Cellular Immunotherapy Revenue by Application (2021-2032)
  7. 9.4.1 Europe CAR-T Cellular Immunotherapy Revenue by Application (2021-2026)
  8. 9.4.2 Europe CAR-T Cellular Immunotherapy Revenue by Application (2027-2032)
  9. 9.5 Europe CAR-T Cellular Immunotherapy Revenue Share by Application (2021-2032)
  10. 9.6 Europe CAR-T Cellular Immunotherapy Revenue by Country
  11. 9.6.1 Europe CAR-T Cellular Immunotherapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe CAR-T Cellular Immunotherapy Revenue by Country (2021-2026)
  13. 9.6.3 Europe CAR-T Cellular Immunotherapy Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
  19. 9.6.9 Nordic Countries
10 China
  1. 10.1 China CAR-T Cellular Immunotherapy Revenue (2021-2032)
  2. 10.2 China CAR-T Cellular Immunotherapy Revenue by Type (2021-2032)
  3. 10.2.1 China CAR-T Cellular Immunotherapy Revenue by Type (2021-2026)
  4. 10.2.2 China CAR-T Cellular Immunotherapy Revenue by Type (2027-2032)
  5. 10.3 China CAR-T Cellular Immunotherapy Revenue Share by Type (2021-2032)
  6. 10.4 China CAR-T Cellular Immunotherapy Revenue by Application (2021-2032)
  7. 10.4.1 China CAR-T Cellular Immunotherapy Revenue by Application (2021-2026)
  8. 10.4.2 China CAR-T Cellular Immunotherapy Revenue by Application (2027-2032)
  9. 10.5 China CAR-T Cellular Immunotherapy Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia CAR-T Cellular Immunotherapy Revenue (2021-2032)
  2. 11.2 Asia CAR-T Cellular Immunotherapy Revenue by Type (2021-2032)
  3. 11.2.1 Asia CAR-T Cellular Immunotherapy Revenue by Type (2021-2026)
  4. 11.2.2 Asia CAR-T Cellular Immunotherapy Revenue by Type (2027-2032)
  5. 11.3 Asia CAR-T Cellular Immunotherapy Revenue Share by Type (2021-2032)
  6. 11.4 Asia CAR-T Cellular Immunotherapy Revenue by Application (2021-2032)
  7. 11.4.1 Asia CAR-T Cellular Immunotherapy Revenue by Application (2021-2026)
  8. 11.4.2 Asia CAR-T Cellular Immunotherapy Revenue by Application (2027-2032)
  9. 11.5 Asia CAR-T Cellular Immunotherapy Revenue Share by Application (2021-2032)
  10. 11.6 Asia CAR-T Cellular Immunotherapy Revenue by Country
  11. 11.6.1 Asia CAR-T Cellular Immunotherapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia CAR-T Cellular Immunotherapy Revenue by Country (2021-2026)
  13. 11.6.3 Asia CAR-T Cellular Immunotherapy Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA CAR-T Cellular Immunotherapy Revenue (2021-2032)
  2. 12.2 SAMEA CAR-T Cellular Immunotherapy Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA CAR-T Cellular Immunotherapy Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA CAR-T Cellular Immunotherapy Revenue by Type (2027-2032)
  5. 12.3 SAMEA CAR-T Cellular Immunotherapy Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA CAR-T Cellular Immunotherapy Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA CAR-T Cellular Immunotherapy Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA CAR-T Cellular Immunotherapy Revenue by Application (2027-2032)
  9. 12.5 SAMEA CAR-T Cellular Immunotherapy Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA CAR-T Cellular Immunotherapy Revenue by Country
  11. 12.6.1 SAMEA CAR-T Cellular Immunotherapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA CAR-T Cellular Immunotherapy Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA CAR-T Cellular Immunotherapy Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst